ERBB2 and breast cancer: More recently, in the field of treating BC, results from the CREATE-X trial showed that the addition of capecitabine has a statistically significant survival advantage in human epidermal growth factor receptor 2 (HER2)-negative residual invasive BC patients with no pathologic complete response after NAC.